Citation： 陆安清,李卡,蒋理立. Application of PET/CT in Diagnosis of Recurrence and Metastasis of Colorectal Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2012, 19(7): 790-792. doi: Copy
Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. | 陈万青， 张思维， 郑荣寿， 等. 中国肿瘤登记地区2007 年肿瘤发病和死亡分析 [J]. 中国肿瘤， 2011， 20(3)：162-169. |
| 2. | Bar-Shalom R， Valdivia AY， Blaufox MD. PET imaging in oncology [J]. Semin Nucl Med， 2000， 30(3)：150-185. |
| 3. | Strauss LG， Conti PS. The application of PET in clinical oncology [J]. J Nucl Med， 1991， 32(4)：623-648；649-650. |
| 4. | Bomanji JB， Costa DC， Ell PJ. Clinical role of positron emission tomography in oncology [J]. Lancet Oncol， 2001， 2(3)：157-164. |
| 5. | Hustinx R， Bénard F， Alavi A. Who body FDG-PET imaging in the management of patient with cancer [J]. Semin Nucl Med，2002， 32(1)：35-46. |
| 6. | Smith TA. FDG uptake， tumor characteristics and response to therapy：a review [J]. Nucl Med Commun， 1998， 19(2)：97-105. |
| 7. | Ruers TJ， Langenhoff BS， Neeleman N， et al. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases：a prospective study [J]. J Clin Oncol， 2002， 20(2)：388-395. |
| 8. | Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT [J]. J Nucl Med， 2004， 45 Suppl 1：82S-95S. |
| 9. | Beyer T， Townsend DW， Brun T， et al. A combined PET/CT scanner for clinical oncology [J]. J Nucl Med， 2000， 41(8)：1369-1379. |
| 10. | Antoch G， Saoudi N， Kuehl H， et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors：comparison with CT and PET [J]. J Clin Oncol， 2004， 22(21)：4357-4368. |
| 11. | Selzner M， Hany TF， Wildbrett P， et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? [J]. J Clin Oncol， 2004，240(6)：1027-1034. |
| 12. | Malik EJ， Bruce DC. Positron-emission tomography and assessment of cancer therapy [J]. N Engl J Med， 2006， 354(5)：496-507. |
| 13. | Israel O， Kuten A. Early detection of cancer recurrence：18FFDG PET/CT can make a difference in diagnosis and patient care [J]. J Nucl Med， 2007， 48 Suppl 1：28S-35S. |
| 14. | Kim JH， Czernin J， Allen-Auerbach MS， et al. Comparison between 18F-FDG PET， in-line PET/CT， and software fusion for restaging of recurrent colorectal cancer [J]. J Nucl Med， 2005，46(4)：587-595. |
| 15. | Even-Sapir E， Parag Y， Lerman H， et al. Detection of recurrence in patients with rectal cancer PET/CT after abdominoperineal or anterior resection [J]. Radiology， 2004， 232(3)：815-822. |
| 16. | Israel O， Mor M， Guralnik L， et al. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? [J]. J Nucl Med， 2004， 45(12)：2045-2051. |
| 17. | Nakamoto Y， Sakamoto S， Okada T， et al. Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer [J]. AJR Am J Roentgenol， 2007，188(1)：257-267. |
| 18. | Votrubova J， Belohlavek O， Jaruskova M， et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer [J].Eur J Nucl Med Mol Imaging， 2006， 33(7)：779-784. |
| 19. | 刘松涛， 周存生， 王莉， 等. PET/CT 显像在直肠癌术后局部复发诊断中的价值 [J]. 山东医药， 2006， 46(23)：3-4. |
| 20. | 张悦， 高硕， 李亚军， 等. 结直肠癌术后癌胚抗原水平升高者行18F-FDG PET/CT 显像的价值 [J]. 中华普通外科杂志，2007， 22(6)：466-467. |
| 21. | 汪延明， 赵修义， 吕晓彦， 等. 18F-FDG PET-CT 及血清CEA检测在结直肠癌术后诊断及治疗中的临床应用价值 [J]. 中华临床医师杂志( 电子版)， 2008， 2(8)：865-871. |
| 22. | Scheele J. Hepatectomy for liver metastases [J]. Br J Surg，1993， 80(3)：274-276. |
| 23. | 季加孚. 结直肠癌肝转移的治疗策略 [J]. 中国实用外科杂志，2004，24(7)：398-400. |
| 24. | Fortner JG， Silva JS， Golbey RB， et al. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer [J]. Ann Surg， 1984， 199(3)：306-316. |
| 25. | Adson MA， van Heerden JA， Adson MH， et al. Resection of hepatic metastases from colorectal cancer [J]. Arch Surg， 1984，119(6)：647-651. |
| 26. | Kevin S， Rebecca B， Sate MS， et al. Resection of the liver for colorectal carcinoma metastases：a multi-institutional study of indications for resection [J]. Surgery， 1988， 103(3)：278-288. |
| 27. | Scheele J， Stang R， Altendorf-Hofmann A， et al. Resection of colorectal liver metastases [J]. World J Surg， 1995， 19(1)：59-71. |
| 28. | Nordlinger B， Guiguet M， Vaillant JC， et al. Surgical resection of colorectal carcinoma metastases to the liver A prognostic scoring system to improve case selection， based on 1 568 patients [J]. Cancer， 1996， 77(7)：1254-1262. |
| 29. | Adam R， Vinet E. Regional treatment of metastasis：surgery of colorectal liver metastases [J]. Ann Oncol， 2004， 15 Suppl 4：103-106. |
| 30. | 周总光， 赵玉沛. 外科学 [M]. 北京：高等教育出版社， 2009：465. |
| 31. | 周伟平， 吴孟超. 结直肠癌肝转移的治疗进展 [J]. 中华胃肠外科杂志， 2005， 8(1)：9-10. |
| 32. | Bismuth H， Adam R， Lévi F， et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy [J]. Ann Surg， 1996， 224(4)：509-520. |
| 33. | Adam R， Avisar E， Ariche A， et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [J]. Ann Surg Oncol， 2001， 8(4)：347-353. |
| 34. | Allen PJ， Kemeny N， Jarnagin W， et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases [J]. J Gastrointest Surg，2003， 7(1)：109-115. |
| 35. | Giacchetti S， Itzhaki M， Gruia G， et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil， leucovorin，oxaliplatin and surgery [J]. Ann Oncol， 1999， 10(6)：663-669. |
| 36. | Giacchetti S， Perpoint B， Zidani R， et al. Phase Ⅲ multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [J]. J Clin Oncol， 2000， 18(1)：136-147. |
| 37. | Selzner M， Hany TF， Wildbrett P， et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? [J]. Ann Surg， 2004，240(6)：1027-1034. |
| 38. | Veit P， Antoch G， Stergar H， et al. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT：initial results [J]. Eur Radiol， 2006， 16(1)：80-87. |
| 39. | Herbertson RA， Lee ST， Tebbutt N， et al. The expanding role of PET technology in the management of patients with colorectal cancer [J]. Ann Oncol， 2007， 18(11)：1774-1781. |
| 40. | Paskeviciute B， Bölling T， Brinkmann M， et al. Impact of (18) FFDG-PET/CT on staging and irradiation of patients with locallyadvanced rectal cancer [J]. Strahlenther Onkol， 2009， 185(4)：260-265. |
| 41. | Ciernik IF， Dizendorf E， Baumert BG， et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT)：a feasibility study [J]. Int J Radiat Oncol Biol Phys， 2003， 57(3)：853-863. |
| 42. | Zubeldia JM， Bednarczyk EM， Baker JG， et al. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases [J].Cancer Biother Radiopharm， 2005， 20(4)：450-456. |
- 1. 陈万青， 张思维， 郑荣寿， 等. 中国肿瘤登记地区2007 年肿瘤发病和死亡分析 [J]. 中国肿瘤， 2011， 20(3)：162-169.
- 2. Bar-Shalom R， Valdivia AY， Blaufox MD. PET imaging in oncology [J]. Semin Nucl Med， 2000， 30(3)：150-185.
- 3. Strauss LG， Conti PS. The application of PET in clinical oncology [J]. J Nucl Med， 1991， 32(4)：623-648；649-650.
- 4. Bomanji JB， Costa DC， Ell PJ. Clinical role of positron emission tomography in oncology [J]. Lancet Oncol， 2001， 2(3)：157-164.
- 5. Hustinx R， Bénard F， Alavi A. Who body FDG-PET imaging in the management of patient with cancer [J]. Semin Nucl Med，2002， 32(1)：35-46.
- 6. Smith TA. FDG uptake， tumor characteristics and response to therapy：a review [J]. Nucl Med Commun， 1998， 19(2)：97-105.
- 7. Ruers TJ， Langenhoff BS， Neeleman N， et al. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases：a prospective study [J]. J Clin Oncol， 2002， 20(2)：388-395.
- 8. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT [J]. J Nucl Med， 2004， 45 Suppl 1：82S-95S.
- 9. Beyer T， Townsend DW， Brun T， et al. A combined PET/CT scanner for clinical oncology [J]. J Nucl Med， 2000， 41(8)：1369-1379.
- 10. Antoch G， Saoudi N， Kuehl H， et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors：comparison with CT and PET [J]. J Clin Oncol， 2004， 22(21)：4357-4368.
- 11. Selzner M， Hany TF， Wildbrett P， et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? [J]. J Clin Oncol， 2004，240(6)：1027-1034.
- 12. Malik EJ， Bruce DC. Positron-emission tomography and assessment of cancer therapy [J]. N Engl J Med， 2006， 354(5)：496-507.
- 13. Israel O， Kuten A. Early detection of cancer recurrence：18FFDG PET/CT can make a difference in diagnosis and patient care [J]. J Nucl Med， 2007， 48 Suppl 1：28S-35S.
- 14. Kim JH， Czernin J， Allen-Auerbach MS， et al. Comparison between 18F-FDG PET， in-line PET/CT， and software fusion for restaging of recurrent colorectal cancer [J]. J Nucl Med， 2005，46(4)：587-595.
- 15. Even-Sapir E， Parag Y， Lerman H， et al. Detection of recurrence in patients with rectal cancer PET/CT after abdominoperineal or anterior resection [J]. Radiology， 2004， 232(3)：815-822.
- 16. Israel O， Mor M， Guralnik L， et al. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? [J]. J Nucl Med， 2004， 45(12)：2045-2051.
- 17. Nakamoto Y， Sakamoto S， Okada T， et al. Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer [J]. AJR Am J Roentgenol， 2007，188(1)：257-267.
- 18. Votrubova J， Belohlavek O， Jaruskova M， et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer [J].Eur J Nucl Med Mol Imaging， 2006， 33(7)：779-784.
- 19. 刘松涛， 周存生， 王莉， 等. PET/CT 显像在直肠癌术后局部复发诊断中的价值 [J]. 山东医药， 2006， 46(23)：3-4.
- 20. 张悦， 高硕， 李亚军， 等. 结直肠癌术后癌胚抗原水平升高者行18F-FDG PET/CT 显像的价值 [J]. 中华普通外科杂志，2007， 22(6)：466-467.
- 21. 汪延明， 赵修义， 吕晓彦， 等. 18F-FDG PET-CT 及血清CEA检测在结直肠癌术后诊断及治疗中的临床应用价值 [J]. 中华临床医师杂志( 电子版)， 2008， 2(8)：865-871.
- 22. Scheele J. Hepatectomy for liver metastases [J]. Br J Surg，1993， 80(3)：274-276.
- 23. 季加孚. 结直肠癌肝转移的治疗策略 [J]. 中国实用外科杂志，2004，24(7)：398-400.
- 24. Fortner JG， Silva JS， Golbey RB， et al. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer [J]. Ann Surg， 1984， 199(3)：306-316.
- 25. Adson MA， van Heerden JA， Adson MH， et al. Resection of hepatic metastases from colorectal cancer [J]. Arch Surg， 1984，119(6)：647-651.
- 26. Kevin S， Rebecca B， Sate MS， et al. Resection of the liver for colorectal carcinoma metastases：a multi-institutional study of indications for resection [J]. Surgery， 1988， 103(3)：278-288.
- 27. Scheele J， Stang R， Altendorf-Hofmann A， et al. Resection of colorectal liver metastases [J]. World J Surg， 1995， 19(1)：59-71.
- 28. Nordlinger B， Guiguet M， Vaillant JC， et al. Surgical resection of colorectal carcinoma metastases to the liver A prognostic scoring system to improve case selection， based on 1 568 patients [J]. Cancer， 1996， 77(7)：1254-1262.
- 29. Adam R， Vinet E. Regional treatment of metastasis：surgery of colorectal liver metastases [J]. Ann Oncol， 2004， 15 Suppl 4：103-106.
- 30. 周总光， 赵玉沛. 外科学 [M]. 北京：高等教育出版社， 2009：465.
- 31. 周伟平， 吴孟超. 结直肠癌肝转移的治疗进展 [J]. 中华胃肠外科杂志， 2005， 8(1)：9-10.
- 32. Bismuth H， Adam R， Lévi F， et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy [J]. Ann Surg， 1996， 224(4)：509-520.
- 33. Adam R， Avisar E， Ariche A， et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [J]. Ann Surg Oncol， 2001， 8(4)：347-353.
- 34. Allen PJ， Kemeny N， Jarnagin W， et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases [J]. J Gastrointest Surg，2003， 7(1)：109-115.
- 35. Giacchetti S， Itzhaki M， Gruia G， et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil， leucovorin，oxaliplatin and surgery [J]. Ann Oncol， 1999， 10(6)：663-669.
- 36. Giacchetti S， Perpoint B， Zidani R， et al. Phase Ⅲ multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [J]. J Clin Oncol， 2000， 18(1)：136-147.
- 37. Selzner M， Hany TF， Wildbrett P， et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? [J]. Ann Surg， 2004，240(6)：1027-1034.
- 38. Veit P， Antoch G， Stergar H， et al. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT：initial results [J]. Eur Radiol， 2006， 16(1)：80-87.
- 39. Herbertson RA， Lee ST， Tebbutt N， et al. The expanding role of PET technology in the management of patients with colorectal cancer [J]. Ann Oncol， 2007， 18(11)：1774-1781.
- 40. Paskeviciute B， Bölling T， Brinkmann M， et al. Impact of (18) FFDG-PET/CT on staging and irradiation of patients with locallyadvanced rectal cancer [J]. Strahlenther Onkol， 2009， 185(4)：260-265.
- 41. Ciernik IF， Dizendorf E， Baumert BG， et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT)：a feasibility study [J]. Int J Radiat Oncol Biol Phys， 2003， 57(3)：853-863.
- 42. Zubeldia JM， Bednarczyk EM， Baker JG， et al. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases [J].Cancer Biother Radiopharm， 2005， 20(4)：450-456.